Oxybutynin Chloride
Product Images NDC 43353-769

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 43353-769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 10mg (43353 769)

Label for Oxybutynin Chloride ER 10 mg tablets, containing 1600 tablets. The label includes storage instructions, manufacturer information (Kremers Urban Pharmaceuticals Inc., Princeton, NJ), and repackager details (Aphena Pharma Solutions - Tennessee, Inc., Cookeville, TN). It specifies that the product is RX only and includes barcode and NDC number 43353-0769-41.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Oxybutynin 01)

Chemical structure diagram of Oxybutynin Chloride showing molecular bonds and functional groups as part of the active ingredient composition.*

FDA Label Image

Figure (Oxybutynin 02)

A line graph comparing mean plasma R-oxybutynin concentration (ng/mL) over 24 hours for oxybutynin chloride extended-release tablets 10 mg once daily (QD) versus oxybutynin 5 mg three times daily (TID). The x-axis represents time in hours, and the y-axis shows drug concentration, with error bars indicating variability.*

FDA Label Image

Figure (Oxybutynin 03)

A line graph depicting the mean R-Oxybutynin plasma concentration (ng/mL) over time in hours, ranging from 0 to 24 hours. Data points show concentration values around 0.5 to 0.7 ng/mL with error bars indicating variability at each time point.*

FDA Label Image

Figure (Oxybutynin 04)

A horizontal error bar chart depicting mean change in episodes per week from baseline for oxybutynin chloride extended-release tablets compared to placebo. The x-axis ranges from -40 to 40, with data points and error bars shown for each group, indicating variability (±SD) in the measured episodes.*

FDA Label Image

Figure (Oxybutynin 05)

A horizontal bar chart illustrating the mean change (±SD) in episodes per week from baseline for oxybutynin chloride extended-release tablets compared to oxybutynin. The x-axis represents the mean change in episodes ranging from -40 to 40.*

FDA Label Image

Figure (Oxybutynin 06)

A horizontal bar chart showing the mean change in episodes per week from baseline for oxybutynin chloride extended-release tablets and oxybutynin, with error bars indicating standard deviation. The chart's x-axis ranges from -40 to 40, illustrating the treatment effects on episodes over time.*

FDA Label Image

Company Logo (Oxybutynin 07)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.